Publicacións nas que colabora con EVA ALLONCA CAMPA (12)

2020

  1. Expression of E-cadherin and β-catenin in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas

    Acta Otorrinolaringologica Espanola, Vol. 71, Núm. 6, pp. 358-366

  2. Impact of notch signaling on the prognosis of patients with head and neck squamous cell carcinoma

    Oral Oncology, Vol. 110

  3. Lectin-like transcript 1 (LLT1) checkpoint: A novel independent prognostic factor in HPV-negative oropharyngeal squamous cell carcinoma

    Biomedicines, Vol. 8, Núm. 12, pp. 1-14

  4. Prognostic significance of the pluripotency factors NANOG, SOX2, and OCT4 in head and neck squamous cell carcinomas

    Cancers, Vol. 12, Núm. 7, pp. 1-15

2019

  1. SOX2 expression is an independent predictor of oral cancer progression

    Journal of Clinical Medicine, Vol. 8, Núm. 10

  2. The SRC inhibitor dasatinib induces stem cell-like properties in head and neck cancer cells that are effectively counteracted by the mithralog EC-8042

    Journal of Clinical Medicine, Vol. 8, Núm. 8

  3. The differential impact of SRC expression on the prognosis of patients with head and neck squamous cell carcinoma

    Cancers, Vol. 11, Núm. 11

2018

  1. Distinctive expression and amplification of genes at 11q13 in relation to HPV status with impact on survival in head and neck cancer patients

    Journal of Clinical Medicine, Vol. 7, Núm. 12

  2. Immunohistochemical expression of cortactin and focal adhesion kinase predicts recurrence risk and laryngeal cancer risk beyond histologic grading

    Cancer Epidemiology Biomarkers and Prevention, Vol. 27, Núm. 7, pp. 805-813

2017

  1. A Novel Role for Nanog As An Early Cancer Risk Marker in Patients with Laryngeal Precancerous Lesions

    Scientific Reports, Vol. 7, Núm. 1

  2. Prognostic significance of E-cadherin and β-catenin expression in HPV-negative oropharyngeal squamous cell carcinomas

    Head and Neck, Vol. 39, Núm. 11, pp. 2293-2300

2016

  1. Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas

    Oncotarget, Vol. 7, Núm. 20, pp. 29780-29793